drugset / Trial / NCT02033473

Effect of Apelin on Insulin Sensitivity: Proof of Concept in Healthy Volunteers

NCT02033473

Phase 1 Completed 16 enrolled University Hospital, Toulouse
RandomizedCrossoverQuadruple-blindBasic science

Summary

The (PYR1)-apelin-13 is an endogenous peptide discovered relatively recently (1998). The apelin and its receptor, which is named apj, are expressed in many tissues including sensitive to the action of insulin, such as skeletal muscle, adipose tissue and heart tissue. Recent work by the team of Prof. P.Valet (INSERM U1048, Toulouse) opened a new field of investigation, demonstrating for the first time in mouse models that apelin exerts a glucose-regulating in vivo action. The investigators propose a translational clinical research project whose goal is to provide the proof of concept of the favorable influence of apelin on insulin sensitivity in humans.

Timeline

Start
2014-01
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Apelin Peptide 9 unknown Intravenous
Subject Apelin Peptide 30 unknown Intravenous

Indications

No indication recorded.